Search Published Scientific Projects Competitive Products and Technology Patents
Login
In partnership with Intrexon Corporation, ZIOPHARM is developing two clinical-stage DNA therapeutics, and is exploring a number of applications for this revolutionary technology in the lab, including controlled production in the body of therapeutic antib
Industry:
Pharma
Owner:
Ziopharm
SGI has exclusive access to new inventions and discoveries in synthetic genomics research developed by the JCVI under a sponsored research agreement between both organizations. The firm also sponsors fundamental research at the JCVI. In May this year JCVI
Industry:
Pharma
Owner:
Synthetic Genomics Vaccines, Inc.
Using synthetic biology methods, the Escherichia coli K-12 genome was reduced by making a series of planned, precise deletions. The multiple-deletion series (MDS™) strains (1), with genome reduction of up to 15%, were designed by identifying non-essential
Industry:
Life Sciences
Owner:
Scarab Genomics LLC
Using synthetic biology methods, the Escherichia coli K-12 genome was reduced by making a series of planned, precise deletions. The multiple-deletion series (MDS™) strains (1), with genome reduction of up to 15%, were designed by identifying non-essential
Industry:
Life Sciences
Owner:
Scarab Genomics LLC
Using synthetic biology methods, the Escherichia coli K-12 genome was reduced by making a series of planned, precise deletions. The multiple-deletion series (MDS™) strains (1), with genome reduction of up to 15%, were designed by identifying non-essential
Industry:
Life Sciences
Owner:
Scarab Genomics LLC
Using synthetic biology methods, the Escherichia coli K-12 genome was reduced by making a series of planned, precise deletions. The multiple-deletion series (MDS™) strains (1), with genome reduction of up to 15%, were designed by identifying non-essential
Industry:
Life Sciences
Owner:
Scarab Genomics LLC
Using synthetic biology methods, the Escherichia coli K-12 genome was reduced by making a series of planned, precise deletions. The multiple-deletion series (MDS™) strains (1), with genome reduction of up to 15%, were designed by identifying non-essential
Industry:
Life Sciences
Owner:
Scarab Genomics, LLC.
Using synthetic biology methods, the Escherichia coli K-12 genome was reduced by making a series of planned, precise deletions. The multiple-deletion series (MDS™) strains (1), with genome reduction of up to 15%, were designed by identifying non-essential
Industry:
Life Sciences
Owner:
Scarab Genomics LLC
sing synthetic biology methods, the Escherichia coli K-12 genome was reduced by making a series of planned, precise deletions. The multiple-deletion series (MDS™) strains (1), with genome reduction of up to 15%, were designed by identifying non-essential
Industry:
Life Sciences
Owner:
Scarab Genomics LLC
Using synthetic biology methods, the Escherichia coli K-12 genome was reduced by making a series of planned, precise deletions. The multiple-deletion series (MDS™) strains (1), with genome reduction of up to 15%, were designed by identifying non-essential
Industry:
Life Sciences
Owner:
Scarab Genomics LLC
Using synthetic biology methods, the Escherichia coli K-12 genome was reduced by making a series of planned, precise deletions. The multiple-deletion series (MDS™) strains (1), with genome reduction of up to 15%, were designed by identifying non-essential
Industry:
Life Sciences
Owner:
Scarab Genomics LLC
Using synthetic biology methods, the Escherichia coli K-12 genome was reduced by making a series of planned, precise deletions. The multiple-deletion series (MDS™) strains (1), with genome reduction of up to 15%, were designed by identifying non-essential
Industry:
Life Sciences
Owner:
Scarab Genomics, LLC.
sing synthetic biology methods, the Escherichia coli K-12 genome was reduced by making a series of planned, precise deletions. The multiple-deletion series (MDS™) strains (1), with genome reduction of up to 15%, were designed by identifying non-essential
Industry:
Life Sciences
Owner:
Scarab Genomics, LLC.
Using synthetic biology methods, the Escherichia coli K-12 genome was reduced by making a series of planned, precise deletions. The multiple-deletion series (MDS™) strains (1), with genome reduction of up to 15%, were designed by identifying non-essential
Industry:
Life Sciences
Owner:
Scarab Genomics LLC
Scarab Genomics has bioengineered the Clean Genome® E. coli by deleting over 15% of the genome. Genome reduction optimizes the E. coli as a biological factory. Elimination of recombinogenic or mobile DNA, toxins and virulence genes and non-essential genes
Industry:
Life Sciences
Owner:
Scarab Genomics, LLC.
Using synthetic biology methods, the Escherichia coli K-12 genome was reduced by making a series of planned, precise deletions. The multiple-deletion series (MDS™) strains (1), with genome reduction of up to 15%, were designed by identifying non-essential
Industry:
Life Sciences
Owner:
Scarab Genomics LLC
Using synthetic biology methods, the Escherichia coli K-12 genome was reduced by making a series of planned, precise deletions. The multiple-deletion series (MDS™) strains (1), with genome reduction of up to 15%, were designed by identifying non-essential
Industry:
Life Sciences
Owner:
Scarab Genomics LLC
Using synthetic biology methods, the Escherichia coli K-12 genome was reduced by making a series of planned, precise deletions. The multiple-deletion series (MDS™) strains (1), with genome reduction of up to 15%, were designed by identifying non-essential
Industry:
Life Sciences
Owner:
Scarab Genomics, LLC
Using synthetic biology methods, the Escherichia coli K-12 genome was reduced by making a series of planned, precise deletions. The multiple-deletion series (MDS™) strains (1), with genome reduction of up to 15%, were designed by identifying non-essential
Industry:
Life Sciences
Owner:
Scarab Genomics, LLC.
Using synthetic biology methods, the Escherichia coli K-12 genome was reduced by making a series of planned, precise deletions. The multiple-deletion series (MDS™) strains (1), with genome reduction of up to 15%, were designed by identifying non-essential
Industry:
Life Sciences
Owner:
Scarab Genomics, LLC